复星医药：HLX22联合注射用HLX87获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for HLX22 and HLX87 in China, targeting HER2-positive breast cancer [1] Group 1 - The approved clinical trials include a Phase II/III trial for HLX22 as a first-line treatment for HER2-positive breast cancer [1] - A second Phase II/III trial is approved for HLX87 as neoadjuvant therapy for HER2-positive breast cancer [1] - Fuhong Hanlin plans to initiate these clinical studies in China once conditions are met [1]